T A B L E O F C O N T E N

Main results
We identified seven trials, with 895 evaluable participants for this review. All provided data suitable for the primary outcome metaanalysis. One of the trials was new since the last version of this Cochrane systematic review. Risk of bias in the older, smaller studies included some unclear-or high-risk assessments, whereas we deemed the larger studies at low risk of bias. Overall, 79/452 (17%) participants allocated to corticosteroids had incomplete recovery of facial motor function six months or more after randomisation; significantly fewer than the 125/447 (28%) in the control group (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.50 to 0.80, seven trials, n = 895). The number of people who need to be treated with corticosteroids to avoid one incomplete recovery was 10 (95% CI 6 to 20). The reduction in the proportion of participants with cosmetically disabling sequelae six months after randomisation was very similar in the corticosteroid and placebo groups (RR 0.96, 95% CI 0.40 to 2.29, two trials, n = 75, low-quality evidence). However, there was a significant reduction in motor synkinesis during follow-up in participants receiving corticosteroids (RR 0.64, 95% CI 0.45 to 0.91, three trials, n = 485, moderate-quality evidence). Three studies explicitly recorded the absence of adverse effects attributable to corticosteroids. One trial reported that three participants receiving prednisolone had temporary sleep disturbances and two trials gave a detailed account of adverse effects occurring in 93 participants, all non-serious; the combined analysis of data from these three trials found no significant difference in adverse effect rates between people receiving corticosteroids and people receiving placebo (RR 1.04, 95% CI 0.71 to 1.51, n = 715).
Authors' conclusions
The available moderate-to high-quality evidence from randomised controlled trials showed significant benefit from treating Bell's palsy with corticosteroids.
P L A I N L A N G U A G E S U M M A R Y
Corticosteroids for Bell's palsy
Review question
What are the effects of corticosteroids on Bell's palsy?
Background
Bell's palsy is a paralysis or weakness of muscles in the face, usually on one side, with no certain cause. Symptoms usually recover, although not always. Reducing inflammation of the facial nerve using corticosteroid medicines (steroids) is thought to limit nerve damage. This is an update of a review first published in 2002 and last updated in 2010.
Study characteristics
We identified seven clinical trials involving 895 people with one-sided mild, moderate or severe Bell's palsy of unknown cause. All of these trials reported rates of incomplete recovery (the proportion of people left with facial weakness) and we were able to combine the results. People in the studies were aged from 2 to 84 years. They were treated with corticosteroids or placebo (inactive treatment), either alone or in combination with other therapies. One trial only involved children, from 24 months to 74 months old. The duration of the included studies for adults and children ranged from 157 days to 12 months.
Key results and quality of the evidence
Incomplete recovery
According to moderate quality to high quality evidence, corticosteroids reduced the number of people left with facial weakness after Bell's palsy compared to placebo (a pretend medicine). This finding was based on data from seven studies involving 895 participants with Bell's palsy of varying degrees of severity. We calculated that to stop one person from being left with facial weakness, 10 people need to be treated.
Five studies provided data on long-term after-effects of Bell's palsy following treatment. Two of the studies (75 participants) looked at persistent effects on facial appearance after six months or more. The effect was nearly the same for corticosteroids and placebo, showing that participants who had corticosteroids benefited slightly, although this evidence was low quality. Data from three studies (485 participants) showed clearly that people who received corticosteroids developed less motor synkinesis (unwanted facial movements) and crocodile tears (watery eyes when eating or chewing), compared with people who received placebo alone. This finding was based on moderate-quality evidence.
B A C K G R O U N D Description of the condition
Bell's palsy is an acute, generally unilateral, paralysis or weakness of facial musculature consistent with peripheral facial nerve dysfunction, of no detectable cause (Niparko 1993) . Additional symptoms frequently include pain around or behind the ear sometimes extending into the occipital or cervical region. Impaired tolerance to ordinary levels of noise and disturbed sense of taste on the same side may also be present (Burgess 1984) . Epidemiological studies have reported an annual incidence of 23 to 25 per 100,000 per year (Martyn 1997; Victor 1994) , but one study using a general practitioner (GP) database has suggested it may be even higher at 37 per 100,000 per year (Morales 2013). Bell's palsy affects men and women more or less equally. Until recently was thought to be most common in the 30-to 45-year age group (Bateman 1992; Brandenberg 1993; Katusic 1986; Peitersen 1982; Peitersen 2002; Yanagihara 1988) , although the one more recent primary care database study suggested a peak in people over 70 years of age (Morales 2013). The condition presents disproportionately among pregnant women and people who have diabetes, influenza, a cold, or some other upper respiratory ailment. On average, every year a British GP will see one or two people who have developed the condition. Both sides of the face are affected equally often (Prescott 1988) . The aetiology of Bell's palsy is still debated. A viral infection, vascular ischaemia, autoimmune inflammatory disorders and heredity have been proposed as underlying causes (Adour 1982; Burgess 1984; Lackner 2010) . A viral aetiology has gained popularity since the isolation of herpes simplex virus-1 (HSV-1) genome from the facial nerve endoneurial fluid of people with Bell's palsy (Lackner 2010; Murakami 1996) . The prognosis is on the whole favourable. One of the largest series of people with Bell's palsy including those who were not receiving specific therapy, showed that 85% of people with Bell's palsy began to recover within three weeks of onset (Peitersen 1982) . For the remaining 15%, partial recovery occurred three to six months later. The same series showed that normal facial expression reappeared in 71% of cases, 13% had insignificant sequelae, and the remaining 16% had permanently diminished function with aberrant innervation (expressed as motor synkinesis or autonomic dysfunction) and post-paralytic spasms.
Description of the intervention
The treatment of Bell's palsy used to be highly controversial. Corticosteroids were the treatment of choice, based mainly on nonrandomised comparisons (Adour 1972) . The authors of numerous clinical series both espoused and condemned corticosteroid therapy with, what appeared to them, equally convincing arguments (Burgess 1984) . Four systematic reviews found a significant trend favouring corticosteroid treatment in improving the recovery of facial motor function (de Almeida 2009; Grogan 2001; Ramsey 2000; Williamson 1996) . However, their conclusions were affected by including trials of poor quality in the pooled estimate. de Almeida 2009, a state-of-the-art, high-quality systematic review, differed from our methodology in the way they collected data, in the inclusion of a non-randomised trial that we excluded (Martinez 1990) , and in the exclusion of a trial that we included in our analysis (Taverner 1954) .
How the intervention might work
Corticosteroids are known to have an anti-inflammatory mode of action, which reduces oedema and inflammation of the facial nerve in the acute presentation of Bell's palsy.
Why it is important to do this review
The purpose of this systematic review was to collect and analyse the available evidence from randomised controlled trials concerning the use of corticosteroids for improving the outcome of people with Bell's palsy. This is an update of a review first published in 2002 and last updated in 2010. We updated the review to assess the quality of the evidence regarding the benefit of corticosteroids in Bell's palsy using current methodology, integrate any new evidence and to determine whether further research would be likely to change the estimate of effect or its certainty.
O B J E C T I V E S
To determine the effectiveness and safety of corticosteroid therapy in people with Bell's palsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Trials of the use of corticosteroid therapy for the treatment of recent-onset Bell's palsy in which an attempt had apparently been made to conduct a randomised or quasi-randomised comparison between corticosteroid therapy and a placebo, or open control group. As in the previous version of the review, we used study quality as an exclusion criteria excluding trials with a high risk of bias in several domains.
Types of participants
Participants of any age with clinically diagnosed Bell's palsy, irrespective of the time of evolution of symptoms. We included all participants considered to have Bell's palsy or acute idiopathic facial nerve paralysis by the study authors, irrespective of the ancillary studies they performed to rule out other causes of facial paralysis. We included in the analysis all participants considered eligible by the authors of the studies, irrespective of associated conditions.
Types of interventions
We included trials using any corticosteroid or adrenocorticotrophic hormone therapy, irrespective of the route of administration (oral or parenteral) and length of therapy. We excluded trials in which a drug considered 'effective' for this condition was given to the control group, unless it was given in a similar way to the experimental group. The exception was studies in which control and treatment groups received concomitant antiviral therapy; these are not included in this review, but in the updated Cochrane review 'Antiviral treatment for Bell's palsy (idiopathic facial paralysis)' (Gagyor 2015). We excluded trials comparing different types of corticosteroids or different dosage schemes, unless the trial included a placebo group.
Types of outcome measures
Primary outcomes
• Incomplete recovery of facial motor function six months or more after randomisation.
Secondary outcomes
• Cosmetically disabling persistent sequelae of facial paralysis (poor recovery of facial motor function as defined by the authors of the studies) six months or more after randomisation.
• Motor synkinesis or autonomic dysfunction during followup (including facial spasm, motor synkinesis and crocodile tears).
• Adverse effects attributable to the use of corticosteroids. 
Search methods for identification of studies
Searching other resources
We reviewed the bibliographies of the randomised trials and contacted the study authors and known experts in the field to identify additional published or unpublished data.
Data collection and analysis
Selection of studies
Six review authors scrutinised published and unpublished papers retrieved by the literature searches to select papers for inclusion. At least two review authors independently assessed each paper for relevance, eligibility and quality. There were no disagreements about inclusion. We applied no language limitations.
Data extraction and management
Review authors collected and analysed data in pairs (FG and VM, DS and MS, IG and FS) . We collected data on the following.
• Methods: study design, study duration, number of study centres and location, study setting, withdrawals, and date of study.
• Participants: number (n), mean age, age range, gender, severity of condition, diagnostic criteria, baseline characteristics, inclusion criteria and exclusion criteria.
• Interventions: intervention, comparison, concomitant medications.
• Outcomes: primary and secondary outcomes specified and collected, and time points reported; definition of recovery status.
• Notes: funding for trial and notable conflicts of interest of trial authors.
All six review authors had a selection of papers to read, review for quality and extract data from. At least two review authors assessed each trial. All review authors agreed data extraction. Two review authors (IG and VM) inputted data into Review Manager 5 (RevMan 2014).
Assessment of risk of bias in included studies
IG completed the 'Risk of bias' table. FS and FD individually reviewed the 'Risk of bias' assessments. We assessed bias by scoring studies as at high, low or unclear risk of bias using methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) .
Measures of treatment effect
When comparing studies using different symptom scores to assess outcomes, we used the House-Brackmann scale when available as this was the most widely used or had comparisons to other scales available. When assessing adverse effects, we reported the number of participants affected, as opposed to the number of events, to facilitate data comparison. We used dichotomous outcomes and we analysed data as risk ratios (RR) with a corresponding 95% confidence interval (CI). We calculated a treatment effect using the Mantel-Haenszel method (Egger 2007) .
Unit of analysis issues
Where a single trial included multiple trial arms, we included only arms relevant to this review. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) had been combined in the same meta-analysis, our preference would be to combine groups to create a single comparison if appropriate, or otherwise use one of the other approaches described in Chapter 16 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
One of the trial authors, who is also a review author (FS), provided unpublished trial data. We also contacted a previous study team member (P Lockhart) for additional information on other studies and received a response. We either extracted the number of participants who completed a treatment originally allocated and the number with the outcome, and considered the potential effect of missing data when presenting results, or reported intention-totreat analyses as presented in trial reports. Where data were unavailable we contacted the original authors, when there was no response, we calculated the numbers from the rates and percentages presented in the papers. We undertook no sensitivity analyses for missing values. For some trials, we calculated either number in the analysis or the number experiencing an event using the percentage experiencing an event.
Assessment of heterogeneity
We used the I 2 statistic to measure heterogeneity among the trials in each analysis, using the thresholds in the Cochrane Handbook for Systematic Reviews of Interventions as guidance (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
We interpreted the I 2 statistic in the context of its CI, the Chi 2 test, P value and the size of the effect.
Assessment of reporting biases
Since we were unable to pool more than 10 trials, we could not create a funnel plot to explore possible small-study biases.
Data synthesis
We used a fixed-effect model for our analysis and performed a sensitivity analysis with a random-effects model. If the review had included more than one comparison that could not be included in the same analysis, we would have reported the results for each comparison separately. Throughout we have utilised the following notations: OS: corticosteroid treatment alone OO: placebo or no treatment only Using these notations, we conducted the following comparison: OS versus OO.
'Summary of findings' table
At this update, we added a 'Summary of findings' table. We used the following outcomes: incomplete recovery, cosmetically disabling persistent sequelae six months or more after randomisation, motor synkinesis and crocodile tears, and adverse effects. Under the GRADE approach, the levels of quality of evidence are high, moderate, low or very low. Assessors start at high quality and may downgrade the evidence for the pre-specified outcomes depending on five GRADE considerations, which are: study limitations, consistency of effect, imprecision, indirectness and publication bias. We used methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We used GRADEpro software (GRADEpro 2008) . We have justified all decisions to downgrade or upgrade the quality of studies using footnotes and have made comments to aid readers' understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We did not undertake any subgroup analyses for this review. The protocol detailed possible subgroup analyses, although none were appropriate for the included studies.
Sensitivity analysis
We carried out the following sensitivity analyses.
• Repeated the analyses excluding smaller and underpowered studies.
• Repeated the analyses excluding studies with short-term follow-up (less than nine months).
Description of studies
Results of the search
In the updated searches for this review, we found 59 references in the Cochrane Neuromuscular Specialised Register, 81 in CEN-TRAL, 818 in MEDLINE, 117 in EMBASE and 15 in LILACS. There were seven completed randomised controlled trials comparing corticosteroids with no active control when this review was first written. In subsequent updates, review authors identified five other potentially relevant trials (Austin 1993; Bento 1991; Engström 2008; Lagalla 2002; Sullivan 2007) . In all, seven trials including 895 evaluable participants met our inclusion criteria (Austin 1993; Engström 2008; Lagalla 2002; May 1976; Sullivan 2007; Taverner 1954; Unuvar 1999) . See Figure 1 for a flow chart illustrating the study selection process for this update. The previous update of this review, Salinas 2010, listed seven excluded studies (Akpinar 1979; Austin 1993; Bento 1991; Bento 1994; Brown 1982; Martinez 1990; Wolf 1978) . We have linked two references previously listed as separate trials (Bento 1991 and Bento 1994) under one trial identifier in this update (Bento 1991). We included Austin 1993, previously excluded because of potential attrition bias, as current practice is to include all trials eligible according to the selection criteria. Authors of the last version of this review included groups receiving antiviral therapy and considered the different comparisons from Engström 2008 and Sullivan 2007 as separate studies (Engström 2008b and Sullivan 2007b) . We did not consider the two antiviraltreated participant groups from those trials in this updated review. These comparisons are included in the companion Cochrane review, 'Antiviral treatment for Bell's palsy (idiopathic facial paralysis) ' (Gagyor 2015) . In this update, we included only the comparisons of corticosteroid versus placebo or corticosteroids versus no treatment.
Included studies
Summary details of the included trials are given in Characteristics of included studies. Austin 1993 recruited 107 participants whose symptoms had occurred within five days of presentation to the study centre. Of these, 31 participants did not return for initial follow-up. The 76 remaining participants subsequently entered a double-blinded randomised controlled study allocating them to a corticosteroid treatment group (prednisone) or a placebo group. The trial authors gave no details about binding or randomisation. Assessment of participants occurred within five days of onset and at "regular intervals until they experienced recovery from their acute paralysis". Final follow-up was at six months after recovery. The trial authors stated, "to be included in the analysis, patients must have completed follow up until their acute recovery occurred." Investigators measured disease status using the House-Brackmann grading system. At first evaluation, participants underwent various tests including blood tests, an audiogram, a nerve excitability test using the maximal stimulation technique and, if indicated, electroneurography. Treatment with prednisone was started at 30 mg twice daily for the first five days followed by a reducing dose stated by the trial authors. The study reported final outcomes on 53 participants at six months after recovery. The primary outcome was time to recovery, for which trial authors found no statistically significant difference between the two groups. Secondary outcomes included facial paralysis grade at onset versus grade at recovery. There was a statistically significant difference in incomplete recovery rates favouring the treatment group: 5/23 participants receiving prednisone had incomplete recovery at six months versus 10/30 participants receiving placebo (RR 0.65, 95% CI 0.26 to 1.65). Investigators found no significant difference in persistence of pain during recovery, with 3/23 participants in the prednisone group still experiencing pain at six months, compared with 4/30 participants in the placebo group (RR 0.98, 95% CI 0.24 to 3.95). Engström 2008 had a factorial design that randomised 829 participants into four treatment groups using a two-stage computerised process. The four treatment groups were prednisolone with placebo, prednisolone with valaciclovir, valaciclovir with placebo, and double placebo. Treatment started within 72 hours of symptom onset. The trial was double-blind (administrator and participant) for assessment of recovery status until the end of follow-up. Participants were assessed at onset, after two weeks (11 to 17 days) and after 1, 2, 3, 6 and 12 months. Trialists measured disease status using the House-Brackmann grading system and the Sunnybrook scale, defining complete recovery status as a Sunnybrook score of 100 and a House-Brackmann grade of I. Data analysis included an assessment of treatment interaction. The study reported a positive effect on recovery time due to prednisolone (comparing recovery rates at 12 months in the prednisolone group with the placebo group). For this review, we analysed the corticosteroid-placebo combination (OS) versus the double placebo combination (OO) 12 months after the onset of facial palsy. Using the Sunnybrook definition, 50/210 participants had an incomplete recovery with prednisolone compared with a greater proportion (73/206) in the placebo group (RR 0.67, 95% CI 0.50 to 0.91). Lagalla 2002 randomised 62 participants within three days of onset of Bell's palsy to high-dose prednisone, 1 g daily for three days, then 0.5 g daily for three days, administered intravenously, using saline solution as a placebo. The age range was 15 to 84 years. Exclusion criteria included peptic ulcer disease, pregnancy, severe hypertension, other neurological conditions, diseases of the ear and previous treatment. As in Taverner 1954, investigators excluded participants with herpes zoster oticus from the analyses (four of the participants initially randomised in Lagalla 2002). The investigators monitored participants for 12 months. They assessed recovery of facial motor function using the House-Brackmann scale. The trial authors reported the development of disabling synkinesis at 12-month follow-up. Lagalla 2002 reported final outcomes on 58 participants at 12 months. In the prednisolone group, 5/30 participants had incomplete recovery, compared with 8/28 participants in the placebo group (RR 0.58, 95% CI 0.22 to 1.57). May 1976 included 51 participants within two days of Bell's palsy onset and reported outcomes using clinical assessment and photographic documentation without a validated scoring system. The trial report did not specify the age range of participants in this double-blinded study. In the intervention group, participants received prednisone 410 mg in descending doses over 10 days. The placebo intervention was vitamins. Trialists excluded people with chronic otitis media, trauma, loss of lacrimation, or recurrent or bilateral palsy. May 1976 was the only study that stated that there was no benefit from corticosteroids for the recovery of Bell's palsy (RR 1.16, 95% CI 0.57 to 2.36). Sullivan 2007 recruited 551 participants to be treated within 72 hours of onset. Participants were randomised by a dedicated remote telephone-computerised mechanism in a two-stage process into four treatment groups in a factorial design: prednisolone with placebo, prednisolone with aciclovir, aciclovir with placebo or dou-ble placebo. Participants received prednisolone 25 mg twice daily for 10 days. The trial was blinded for administrator, participant and assessment of recovery status until the end of follow-up. Assessments took place at onset, after three months and, if participants were still unwell, again after nine months. The investigators measured recovery status on the House-Brackmann scale, with complete recovery defined as House-Brackmann grade I. Data analysis included an assessment of treatment interaction. Sullivan 2007 reported final outcomes on 496 completed participants at three and nine months. In the corticosteroid (OS) group, 5/127 participants had incomplete recovery, compared with 18/ 122 participants in the placebo (OO) group (RR 0.27, 95% CI 0.10 to 0.70). Taverner 1954 was a double-blind trial that included 26 participants with a range of ages from 12 to 76 years within 10 days of onset of Bell's palsy. Participants received either oral cortisone acetate 1 g in descending doses over eight days or placebo tablets. Participants were monitored for up to 157 days. The trial excluded participants with other neurological conditions or diseases of the ear. Taverner 1954 included participants with herpes zoster oticus. These participants were allocated in equal numbers to each treatment arm, and trial authors excluded them from the analyses. The trialists did not used a validated scoring system to measure outcomes. Taverner 1954 used the recovery of facial motor function as the main outcome measure and reported a small, non-significant benefit of corticosteroids compared with placebo; CIs allowed for effects in either direction (RR 0.86, 95% CI 0.27 to 2.71). Unuvar 1999 conducted a non-blinded, randomised controlled trial on children with severe to complete presentation of Bell's palsy (House-Brackmann grades IV to V). They randomised 42 children with an age range of 24 to 74 months using a computergenerated random sequence into two groups. All participants entered the trial within three days of onset of Bell's palsy and received either methylprednisolone 1 mg/kg daily for 10 days then gradually withdrawn over three to five days or no specific treatment. They excluded participants with other neurological conditions, diseases of the ear or systemic diseases. The primary outcome was the recovery of facial motor function measured on the HouseBrackmann facial grading system. Unuvar 1999 reported a benefit from the treatment with corticosteroids although wide CIs allowed for the possibility of both no effect and a large effect (RR 0.14, 95% CI 0.01 to 2.61).
Ongoing studies
We identified one trial report on the World Health Organization International Clinical Trials Registry Platform search portal (Babl 2015) . From the website, it appeared that the study has now started recruitment; we will assess this trial fully in future review updates. See Characteristics of ongoing studies.
Excluded studies
Akpinar 1979 compared three groups of 10 participants each; two groups received different dosage regimens of corticosteroids, and the other received placebo. It was unclear who diagnosed the participants with Bell's palsy and there were varying dosage regimens of corticosteroids used. Two studies were not randomised or quasi-randomised (Brown 1982; Martinez 1990) . It was not possible to extract complete information on the specified outcomes for one study (Wolf 1978) . Finally, we excluded Bento 1991 as number of participants and outcome events by treatment groups was not provided; in addition, 50% of the participants were lost to follow-up. 
Risk of bias in included studies
Other potential sources of bias
We identified no other potential sources of bias. 
Effects of interventions
Primary outcome
Incomplete recovery of facial motor function six months or more after randomisation All seven trials, with 895 participants, provided data for the outcome complete recovery of facial motor function at six months' follow-up or more (we included data from Taverner 1954, which reported at five months). The number of people with incomplete recovery at six months' follow-up was lower in the corticosteroid group compared to the control group (RR 0.63, 95% CI 0.50 to 0.80) (Analysis 1.1; Figure 3) . The tests for statistical heterogeneity were marginally significant (Chi 2 = 7.32, P value = 0.29, I 2 = 18%). This small degree of heterogeneity was due to the differences in the findings between the large studies ( 
Sensitivity analyses
We removed smaller underpowered studies (Austin 1993; Lagalla 2002; May 1976; Taverner 1954; Unuvar 1999 ) from the main analysis leaving the two largest studies (Engström 2008; Sullivan 2007) . This analysis confirmed the size and direction of effect, but with higher statistical heterogeneity (RR 0.59, 95% CI 0.44 to 0.79, Chi 2 = 3.32, I 2 = 70%).
We analysed the main outcome for the studies that had the longest follow-up (i.e. between nine and 12 months) (Engström 2008; Lagalla 2002; Sullivan 2007 ). This did not significantly change the result.
Secondary outcomes
Cosmetically disabling persistent sequelae six months or more after randomisation
Two trials with 75 participants provided data on the number of participants with severe paralysis, or what may be judged as cosmetically disabling sequelae, at six months' follow-up or more (May 1976; Taverner 1954) . When we combined the data, the number of participants with cosmetically disabling sequelae was similar in the corticosteroid group and the control group (RR 0.96, 95% CI 0.40 to 2.29) (Analysis 1.2; Figure 4 ) Figure 6 ). 
Subgroup analyses
In this updated version of the review, we did not perform any subgroup analyses.
D I S C U S S I O N Summary of main results
High-quality evidence from randomised controlled trials indicated benefit from the use of corticosteroids in Bell's palsy. Two trials reached a statistically significant difference favouring the use of prednisolone (Engström 2008; Sullivan 2007) . Meta-analysis of the complete high-quality randomised controlled trial literature convincingly supported a beneficial effect of prednisolone for reducing the numbers of participants with incomplete recovery.
Moderate-quality evidence indicated that participants who received corticosteroid treatment had less motor synkinesis and crocodile tears than the placebo group. Based on these two studies, low-quality evidence revealed no important differences between corticosteroids and placebo in cosmetically disabling persistent sequelae, but wide CIs allowed for the possibility of an effect in either direction. The included studies did not report differences in the occurrence of adverse effects between corticosteroids and placebo and additionally no serious adverse effects were reported. However, corticosteroids have well-known adverse effects, of which the incidence rises markedly with prolonged dosages above 10 mg of prednisolone or its equivalent per day (Dollery 1999). Usually corticosteroid courses in Bell's palsy are short and the dose quickly reduces, making the likelihood of adverse effects in practical use less than in longer-term indications.
Overall completeness and applicability of evidence
No new studies have been published since the previous Cochrane review (Salinas 2010 
Quality of the evidence
For the main outcome of this review (incomplete recovery six months or more after randomisation), all seven studies combined provided high-quality evidence. In addition, for motor synkinesis and crocodile tears, data from three studies provided moderate-quality evidence. Cosmetically disabling persistent sequelae six months or more after randomisation was the only analysis performed where the quality of evidence was low. For adverse effects, the evidence was moderate quality. Reasons for downgrading the quality of evidence were that in one study participants and assessors were not blinded to the treatment that they received (Unuvar 1999), and in another study, loss to follow-up was 50%, representing incomplete outcome data (Austin 1993). Two studies excluded participants who were found after randomisation to have clinical evidence of herpes zoster infection (Lagalla 2002; Taverner 1954) . Two studies did not use a standardised scale for assessment of facial motor function (May 1976; Taverner 1954) . We considered the effects of these factors on the quality of the evidence insufficient for further downgrading for indirectness of evidence. The results of the majority of studies in this review were consistent with each other, apart from those of one older, smaller study (May 1976) .
Potential biases in the review process
To help ensure that decisions about which studies to include in this review were reproducible, two review authors repeated the process (we divided the studies into three groups). There was no distinction made on the experience and expertise of each author in the reviewing pairs. On applying the eligibility criteria and assessing the relevance of studies, review authors were aware of the names of the study authors, institutions, journal of publication and results. FS and FD did not assess their own trial (Sullivan 2007). There were no final disagreements about which studies should be included. According to previous practice in this review, we excluded several studies and a published abstract that provided insufficient information. Therefore, there might be some risk of publication and selective reporting bias due to data from some studies being unavailable.
Agreements and disagreements with other studies or reviews
Our results are coincident with three previous systematic reviews, which found that corticosteroids significantly improved the prognosis of people with Bell's palsy (de Almeida 2009; Ramsey 2000; Williamson 1996) . All three reviews, even though of good quality, included a study that lost 50% of participants to follow-up ( 
A U T H O R S ' C O N C L U S I O N S Implications for practice
According to high-quality evidence, 10 people with Bell's palsy need to be treated with corticosteroids to avoid one incomplete recovery. The available evidence from randomised controlled trials shows that corticosteroids significantly reduce the frequency of incomplete recovery from Bell's palsy.
Implications for research
Further research on Bell's palsy treatment should consider giving corticosteroids to those participants acting as controls.
There should be no further studies that do not include corticosteroids as a treatment for Bell's palsy. No participants should be given placebo or no treatment in any future studies. There is an adequate body of evidence to support the use of corticosteroids in the treatment of Bell's palsy.
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The review has some sections in common with the Cochrane review 'Antiviral treatment for Bell's palsy (idiopathic facial paralysis)' (Gagyor 2015), which has been completed in parallel with this review by the same authors.
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Austin 1993
Methods Double-blind, randomised, controlled study Participants 107 people were initially randomised; 76 completed follow-up until acute recovery and were included in the study analyses Participants were treated within 5 days of onset Sex: male 39 (51%), female 37 (49%) Age: mean 36.8 years, range 18 to 70 years 37 cases (49%) right side palsy and 39 cases (51%) left side palsy
Interventions
• Prednisone (n = 35): in a scheduled dosage (30 mg twice daily for 5 days reducing to 20 mg twice daily on day 6, 15 mg twice daily on day 7, 10 mg twice daily on day 8, 5 mg twice daily on day 9, and 5 mg once daily on day 10)
• Equivalent placebo (n = 31) Outcomes Primary outcome:
• time to resolution in days of facial function as defined by the House-Brackmann scale Secondary outcomes:
• distribution of facial nerve grade at 6 months after recovery, in addition to • prednisolone with placebo • valaciclovir with prednisolone • valaciclovir with placebo • double placebo Dosages: valaciclovir 1000 mg 3 times daily for 7 days; prednisolone 60 mg daily for 5 days
Outcomes
Primary outcome:
• recovery of facial function, as assessed at visits with the Sunnybrook scale and the House-Brackmann scale Complete recovery was taken as Sunnybrook scale 100 and House-Brackmann scale grade I Other outcomes:
• degree of pain, as recorded during the first 2 months • adverse effects recorded for the first month • frequency of severe pain, synkinesis, facial spasm and residual facial symptoms at 12 months Follow-up at 2 weeks, and 1, 2, 3, 6 and 12 months after randomisation, according to recovery 
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk Generated by computer number generator. Sequentially numbered identical containers allocated to participants on entry into the trial, by the recruiting physician Allocation concealment (selection bias) Low risk Allocation sequence double-blind and generated by a computer number generator in random permuted blocks of 8
Blinding of participants and personnel (performance bias) All outcomes
Low risk Study drugs issued in identical containers. All participants blinded to treatment group until study completion. All study personnel and data analysts blinded to treatment group until study completion Blinding of outcome assessment (detection bias) All outcomes
Low risk All study personnel and data analysts blinded to treatment group until study completion Incomplete outcome data (attrition bias) All outcomes
Low risk Numbers lost to follow-up and reasons given:
• 213 randomised to corticosteroids: 3 did not receive the drug, 24 lost to followup at 12 months (12.7%); 210 analysed
• 209 randomised to placebo: 3 did not receive the placebo; 18 lost to followup at 12 months; 206 analysed 'Modified' intention-to-treat analyses used. All randomised participants who received at least 1 dose of study medication included, but participants who did not start 
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
A new author team updated this review: Vishnu B Madhok, Ildiko Gagyor, Fergus Daly, Dhruvashree Somasundara, Michael Sullivan, Fiona Gammie, Frank Sullivan.
The review authors added a 'Summary of findings' table and added some sections to the Methods to comply with current Cochrane standards.
Changes from the previous update of this review
When looking at Engström 2008 and Sullivan 2007, we excluded participants that were given antiviral therapy with corticosteroids or antiviral therapy alone as these are reported in a separate review (Gagyor 2015). As a result, in this update we deleted the comparisons from those trials that the previous review authors designated Sullivan b and Engström b.
We assume that the total number of events given in Engström a (i.e. 213) was incorrect, and changed the figure to 210. In the previous Cochrane review, authors used intention-to-treat numbers. We decided to perform available-case analysis unless the trialists reported intention-to-treat data. We deleted Sullivan b from Table 1 .2 "cosmetically disabling persistent sequelae" for the reasons above. Sullivan a did not contribute data to this table.
In Analysis 1.3, "motor synkinesis of or autonomic dysfunction during follow up", we deleted Engström b for the reasons above. In Analysis 1.3, we changed the data for Engström a -the previous Cochrane review correctly gave the number of participants reporting synkinesis at 12 months in the OS group as 32. We continued to use this event rate, but changed the total sample number from 290 to 186 in accordance with the information given. We deleted what was previously Analysis 1.4 "incomplete recovery of patients with Bell's Palsy" as the numbers of participants was negligible (only 22 participants from two studies Sullivan a and May 1976), after we removed the data from Sullivan b. We checked the numbers for May 1976; Taverner 1954; and Unuvar 1999. We found that the numbers included for Taverner were incorrect and updated these in Analysis 1.1. The previous Cochrane review excluded Lagalla 2002 from the main meta-analysis giving the reason that the paper did not provide primary outcome data on complete recovery. We decided to include this study given that we could use information on page 109 (results section) of the paper to calculate the data for input into Analysis 1.1. In the prednisolone group, 32 participants, 83%, had complete recovery, hence 17% (five participants) had incomplete recovery. In the placebo group, there were 30 participants, of whom 25% (eight participants) had incomplete recovery. Based on our changes to Analysis 1.1, the RR changed from 0.51 (95% CI 0.32 to 0.80) to 0.65 (95% CI 0.50 to 0.83).
We added a table of adverse effects (Analysis 1.4). We checked the data for each of the included studies and made significant amendments and corrections in the Effects of interventions section.
In the Objectives, we deleted the reference to 'early' use of corticosteroids in Bell's palsy. 
I N D E X T E R M S Medical Subject Headings (MeSH)
